FOR IMMEDIATE RELEASE

PlantForm, PharmaPraxis establish joint venture

_Biosimilar/biobetter Avastin® first of six biopharmaceutical targets for the Brazilian market_

GUELPH, Ont., Canada and RIO DE JANEIRO, Brazil, June 20, 2014—PlantForm Corporation of Canada and PharmaPraxis of Brazil are pleased to announce the establishment of a joint venture to develop, manufacture and commercialize biosimilar and/or biobetter versions of six key biopharmaceuticals for the Brazilian market, using PlantForm’s low-cost manufacturing system.

The joint venture will first develop a biosimilar/biobetter version of the oncology drug Avastin® (bevacizumab), in collaboration with the Fraunhofer Center for Molecular Biology in Newark, Delaware, USA, which will produce the active pharmaceutical ingredient (API) for clinical trials.

Brazilian government corporation Bio-Manguinhos will also participate in the project. Bio-Manguinhos is responsible for technology development and production of vaccines, reagents and biopharmaceuticals to meet public health demands.

The joint venture will build a pilot cGMP biopharmaceutical manufacturing facility in Brazil.

“PharmaPraxis is pleased to establish this joint venture to bring PlantForm’s innovative, plant-based manufacturing system to Brazil,” said PharmaPraxis CEO Eduardo Cruz. “We aim to significantly reduce the cost of important biopharmaceuticals in order to make these medications more widely available.”

“This joint venture agreement with PharmaPraxis and the support of the Brazilian government is a significant milestone for PlantForm,” said Dr. Don Stewart, PlantForm’s President and CEO. “It advances our global strategy for biosimilar drug development and manufacturing, and we look forward to a highly productive and long-term collaboration.”

“Bio-Manguinhos is investing in Brazil’s biopharmaceutical production capacity, and we are keenly interested in this plant-based technology project and anticipate future engagement,” said Artur Couto, Bio-Manguinhos Director.

About PlantForm Corporation

PlantForm was established in 2008 to commercialize a low-cost, tobacco-plant-based manufacturing system for the production of a wide range of antibody and protein drugs. The platform technology is expected to significantly lower the cost of goods compared to industry-standard mammalian-cell systems for biopharmaceutical production. The company’s pipeline also includes biosimilar Herceptin® (trastuzumab) for breast cancer, and antibodies for the treatment of HIV/AIDS and inflammatory disease. Learn more: www.plantformcorp.com
About PharmaPraxis

PharmaPraxis is a biopharmaceutical technology platform corporation focused on manufacturing and commercializing biosimilar and innovator biologic drugs, pharmacogenomic and genetic kits, and alternative routes for biopharmaceutical expression. The company’s main target areas are genetic disorders, immune inflammatory disorders, cancer, individualized medicine and neglected diseases. PharmaPraxis is part of the Axis Biotec Brasil group of companies, which also includes Silvestre Labs, Cryopraxis and CellPraxis.

-30-

For more information, please contact:

Don Stewart
PlantForm President and CEO
don.stewart@plantformcorp.com
416-452-7242

Stacey Curry Gunn
PlantForm Director of Communications
stacey.curry.gunn@plantformcorp.com
519-827-1131

Eduardo Cruz
PharmaPraxis CEO
ce@axisbiotec.com.br
55 21 3035 69 50

Tatiana Lima
PharmaPraxis Technical Director
pharmapraxis@pharmapraxis.com.br
55 21 2142 7725